Regeneron Launches $200 Million Donation Matching Program to Support Vision Care

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best S&P 500 stocks with huge upside potential. On June 24, Regeneron Pharmaceuticals announced a new and pioneering donation matching program to support Good Days, which is an independent national non-profit charitable organization. The initiative is designed to support Good Days’ Retinal Vascular and Neovascular Disease Fund.

Through this program, Regeneron has committed to matching donations at a one-to-one rate, up to a total of $200 million, for the remainder of the 2025 calendar year. The primary goal is to enable more patients to afford essential medicines that help protect their vision. The Retinal Vascular and Neovascular Disease Fund provides copay assistance to US patients who meet specific criteria determined by Good Days.

The donations are not intended to incentivize the use of any particular product, and copay support is granted without regard to the specific medicine prescribed, as long as it is FDA-approved. Regeneron also facilitates access to medicines through various other initiatives, such as product support & Managed Access Programs, patient assistance programs, and collaborations with experienced stakeholders.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.